Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this a real company? Meaning, is this simply a roll up strategy and growth from acquisition or organic growth to be had? Curious to get some thoughts.
Earnings call today and nice to see the spin off date announced. Any thoughts on this one?
Sorry, Elon Musk.
Will Eli Musk go to jail for his tweet? He should.
Wow, there is a lot of misinformation on this board. I am going to post facts from filings so there is no confusion. from the 10K: https://www.sec.gov/Archives/edgar/data/1165320/000144586618000685/gblx_10k.htm
GBLS retained Fenwick & West, a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to develop strategies for the protection of the Company's intellectual property. The following patents have been filed to date:
Three patent applications (USPTO & PCT)
10/2017_Cannabis-based Formulas to treat Neurodegenerative Disorders (PD, AD, dementia)
02/2018_Cannabis-based Formulas to treat Anti-Inflammatory Disorders (asthma, IBD, etc.)
05/2018_Myrcene-based Formulas to treat Heart Disorders & Pain
Four provisional patent applications (USPTO)
10/2016_Cannabis-based Formulas to treat Neurodegenerative Disorders (PD, AD, dementia)
02/2017_Cannabis-based Formulas to treat Anti-Inflammatory Disorders (asthma, IBD, etc.)
05/2017_Myrcene-based Formulas to treat Heart Disorders & Pain
05/2018_Cannabis-based Formula to Modulate Pain
Two licensed patents complete the GBLS portfolio:
Two licensed patents (USPTO & PCT)
03/2017_Licensed Cannabinoid Receptor-based Heart Disease Patent (approved)
10/2017_Exclusive Worldwide License on Time-Released Cannabinoid Nanoparticles (approved in Spain, applied in the US, Canada, and Europe)
GBLS is collecting research data and intends to file future patents on:
Future Patents in Discovery Phase
Triple-negative breast cancer therapies
Wound healing
HIV/AIDS adjunctive therapy without THC
HAND: HIV Associated Neurocognitive Disorder
For those who missed the new article from SylvaCap today:
https://sylvacap.com/catalysts-are-moving-cannabis-producer-emerald-health-therapeutics/
The float on this one is minimal, less than 100K shares per mgmt. Article from Sylva:
https://sylvacap.com/a-fast-growing-coal-company-with-a-head-of-steam/
Those short Vital had to buy back per the last short interest report: https://www.nasdaq.com/symbol/vtl/short-interest
Short interest was 8.8M shares down to 8.6M shares. Data in September, fingers crossed it is excellent!
Revs moving in the right direction, scams are companies that generate nothing but bullshit which doesn't seem to be the case here. Companies that deliver revenues and cash flow are real. Revenue part, check, cash flow, we will see.
When will this stock get some recognition? $80M in the bank and they who's who of biotech investors in on a preclinical asset. This thing just wallows around in the mire. Get out and tell the story mgmt team.
The preliminary data was excellent, now we must wait on the full set due later this year. In between their could be a business development deal and/or a find that falls in love with the story. Wouldn't that be nice!
Praying!
jbem777, I like your work and nice write up on SNGX. Take a look at the press release on March 3, 2015 entitled: "Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients." Note the quote from SNGX CMO: "This initial dose-ranging clinical trial was specifically designed to examine 3 dose levels of SGX942 versus placebo and, if statistically justified, to continue enrollment in any patient/dose groups in which there was promise of potentially demonstrating a positive and clinically-meaningful outcome," stated Richard Straube, MD, Senior Vice President and Chief Medical Officer of Soligenix. "This positive recommendation from the DRC will allow for a sufficient number of subjects to be enrolled into the most promising dose group to increase the potential of demonstrating a positive effect with SGX942 on this catastrophic side-effect of cancer treatment that remains a significant unmet medical need."
Dr. Straube continued, "Given the additional subjects to be enrolled and our primary endpoint assessment through 11 weeks, timing to top-line results may move into the second half of this year."
Looking forward to the data release :)
How many investigator sponsored trials are currently underway? Also, any idea when U.S. clinical trial will begin and what the indication will be?
Any thoughts on interim data due this month?
Nestle active in medical food arena with recent acquisitions. Anyone familiar with the acquisitions made and if TRGM similar or somewhat similar to companies Nestle has purchased. TRGM stating they will grow revs 30%+ in 2014 according to first quarter earnings release. Look forward to any thoughts.
Based on the recent press release, "El Barqueno impressive both in grade of gold being discovered from surface and also the potential volume of mineralization occurring throughout the targets tested to date." I look forward to additional drill results.
Q3 should be nice. If the company can show year over year improvement and visibility on when they will go EBIT positive, I think we are moving much higher.
The is a significant partnership that will significantly increase revenues. BrickHouse and Duracell partnered already and Duracell launched $20 million plus ad campaign for BrickHouse products. Very encouraging.
I think Dreams really gets rocking after Q4 numbers are announced, we will then see impact of Wal-Mart and JCPenney
The Kalika deal looks to be huge big, 70,000 units plus recurring revs on the units. If each unit goes for $160 (basing my price off competitor devices)that equates to over $11,000,000 in revs from the units alone. Factor in the recurring revs from the units and that is almost $10,000,000 in revs (70,000*$10). This is a $21,000,000 deal based on my math. Is my math off? Any thoughts would be appreciated.
New research on DTVI. Looks like a combination of VRSN, GOOG and GoDaddy.
I still hold. I think the stock goes a lot higher from here, all short term players out and the stock is moving higher which is a good sign.
Vicor now producing revenues. I think the company is at an inflection point, any thoughts?
DRJ up almost 200% in one week, wow.
BIDU of Vietnam is how I am looking at this company. Any thoughts?
JC Penny deal is huge, NCAA deal is also huge. Stock moving well as a result of the news!
I am long SRS big time, I expect a significant correction to take place. I do not understand how the DOW closes up 30 points and SRS is down 15% (Friday). Today DOW down 40 and we are up 3%. In any event, earnings are going to be a disaster and this thing should retest 100 in my opinion.
~$82M in revenues for 2008, not bad considering the world fell apart in the 4th quarter. With signs of a recovery beginning to show, retailers are going to see an inflow of investors money and I believe DRJ doubles before year end. Just my opinion.
Earnings tomorrow, expectation from Vista Partners is for $85M in revenues for 2008. Any thoughts?
Large Bid/Ask spread because the market maker at the AMEX is a crook and due to the fact the stock is thinly traded. This is one of the best companies I have come across in the small cap space.
DRJ rapidly growing top line with 50% yoy growth from online division (FansEdge). New syndication business just landed AOL as a client and I expect that segment to become a major source of revenue for the Company. A competitor in the syndication space is ticker: GSIC. Strong balance sheet, strong management, thinly traded and when institutions faced redemptions, the stock was hit hard. Any thoughts would be appreciated.
Anyone think a correction is coming? DXO rallying well over last few weeks
I am not really sure why the management team made the letter to Avigen public, seems like they are telling investors nobody is interested in them which makes MNOV a short?
GOOG has held its own in this downturn, with the macro outlook improving any thoughts on potential upside? Is GOOG cheap at these levels?